Growth of pancreatic cancers with hemizygous chromosomal 17p loss of MYBBP1A can be preferentially targeted by PARP inhibitors.

Growth of pancreatic cancers with hemizygous chromosomal 17p loss of MYBBP1A can be preferentially targeted by PARP inhibitors.
复制标题

DOI:
10.1126/sciadv.abc4517
复制
发表时间:
2020-12
期刊:
影响因子:
13.6
通讯作者:
Zaret K
Zaret K
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Hsieh A;Pitarresi JR;Lerner J;Donahue G;Hsiehchen D;Rustgi AK;Zaret K

文献摘要

参考文献

相似文献

具有MYBBP1A半合子染色体17p缺失的胰腺癌生长可以优先被PARP抑制剂靶向。在这里,我们选择性地以胰腺导管腺癌(PDAC)细胞为靶细胞,该细胞含有对细胞生长至关重要的半合子基因。MYB结合蛋白1A(MYBBP1A)编码一种染色质结合蛋白,由于染色体17p的缺失也跨越TP53,在大多数PDAC中是半合子的。我们发现,等基因PDAC细胞中的MYBBP1A半合子缺失促进了肿瘤的发生,但矛盾的是,MYBBP1A纯合性缺失与细胞生长受损和肿瘤形成减少有关。多聚腺苷5‘-二磷酸核糖聚合酶1(PARP1)与MYBBP1A相互作用,取代染色质。小分子,如olaparib,将PARP1捕获到染色质,能够驱逐MYBBP1A半合子细胞中最小的染色质结合MYBBP1A蛋白池,并损害细胞生长,比它对野生型细胞的影响更大。我们的发现揭示了与野生型细胞相比,癌细胞中缺失一个等位基因的细胞基本基因如何更容易受到特定分子治疗的影响。
Growth of pancreatic cancers with hemizygous chromosomal 17p loss of MYBBP1A can be preferentially targeted by PARP inhibitors. Here, we selectively target pancreatic ductal adenocarcinoma (PDAC) cells harboring a hemizygous gene essential for cell growth. MYB binding protein 1A (MYBBP1A), encoding a chromatin-bound protein, is hemizygous in most of the PDAC due to a chromosome 17p deletion that also spans TP53. We find that hemizygous MYBBP1A loss in isogenic PDAC cells promotes tumorigenesis but, paradoxically, homozygous MYBBP1A loss is associated with impaired cell growth and decreased tumorigenesis. Poly–adenosine 5′-diphosphate–ribose polymerase 1 (PARP1) interacts with MYBBP1A and displaces it from chromatin. Small molecules, such as olaparib, that trap PARP1 to chromatin are able to evict the minimal pool of chromatin-bound MYBBP1A protein in MYBBP1A hemizygous cells and impair cell growth, greater than its impact on wild-type cells. Our findings reveal how a cell essential gene with one allele lost in cancer cells can be preferentially susceptible to a specific molecular therapy, when compared to wild-type cells.
DOI: 10.1093/nar/gkn1013
发表时间: 2009-03
影响因子: 14.9
作者:
Hara Y;Onishi Y;Oishi K;Miyazaki K;Fukamizu A;Ishida N
通讯作者: Ishida N
DOI: 10.1158/0008-5472.can-06-0721
发表时间: 2006-08-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Calhoun, Eric S.;Hucl, Tomas;Kern, Scott E.
通讯作者: Kern, Scott E.
DOI: 10.1038/sj.onc.1210964
发表时间: 2008-05-08
期刊: ONCOGENE
影响因子: 8
作者:
Al-Azawi, D.;Mc Ilroy, M.;Young, L. S.
通讯作者: Young, L. S.
DOI: 10.1002/1878-0261.12499
发表时间: 2019-07-01
期刊: MOLECULAR ONCOLOGY
影响因子: 6.6
作者:
Felipe-Abrio, Blanca;Verdugo-Sivianes, Eva M.;Carnero, Amancio
通讯作者: Carnero, Amancio
DOI: 10.15252/embj.201592404
发表时间: 2016-03-15
期刊: EMBO JOURNAL
影响因子: 11.4
作者:
Diaferia, Giuseppe R.;Balestrieri, Chiara;Natoli, Gioacchino
通讯作者: Natoli, Gioacchino